60 related articles for article (PubMed ID: 30033945)
1. Factors associated with treatment satisfaction in patients with type 2 diabetes mellitus using oral glucose-lowering agents: a cross-sectional study in urban districts in Japan.
Hayashi I; Watanabe N; Nakata S; Komatsu R; Motoda S; Fujita Y; Ishibashi C; Yamaguchi Baden M; Kimura T; Takahara M; Kozawa J; Imagawa A; Iwahashi H; Shimomura I
Endocr J; 2018 Oct; 65(10):1001-1009. PubMed ID: 30033945
[TBL] [Abstract][Full Text] [Related]
2. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial.
Anderson RT; Narayan KM; Feeney P; Goff D; Ali MK; Simmons DL; Sperl-Hillen JA; Bigger T; Cuddihy R; O'Conner PJ; Sood A; Zhang P; Sullivan MD;
Diabetes Care; 2011 Apr; 34(4):807-12. PubMed ID: 21346183
[TBL] [Abstract][Full Text] [Related]
3. Influence of Supervised Disease Understanding and Diabetes Self-Management on Adherence to Oral Glucose-Lowering Treatment in Patients with Type 2 Diabetes.
Doupis J; Alexandrides T; Elisaf M; Melidonis A; Bousboulas S; Thanopoulou A; Pagkalos EM; Avramidis I; Pappas A; Arvaniti E; Karamousouli E; Voss B; Tentolouris N
Diabetes Ther; 2019 Aug; 10(4):1407-1422. PubMed ID: 31222592
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Medication Compliance in Elderly Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Wakui N; Ozawa M; Yanagiya T; Endo S; Togawa C; Matsuoka R; Shirozu S; Machida Y; Kikuchi M
Front Public Health; 2021; 9():771593. PubMed ID: 35087782
[TBL] [Abstract][Full Text] [Related]
5. Adherence to oral glucose lowering drugs, quality of life, treatment satisfaction and illness perception: A cross-sectional study in patients with type 2 diabetes.
Farhat R; Assaf J; Jabbour H; Licha H; Hajj A; Hallit S; Khabbaz LR
Saudi Pharm J; 2019 Jan; 27(1):126-132. PubMed ID: 30662315
[TBL] [Abstract][Full Text] [Related]
6. Interrelation between patient satisfaction and patient-provider communication in diabetes management.
Cinar AB; Schou L
ScientificWorldJournal; 2014; 2014():372671. PubMed ID: 25614885
[TBL] [Abstract][Full Text] [Related]
7. Using person reported outcomes: Psychometric properties of the German diabetes treatment satisfaction questionnaire (DTSQ) for teens and parents.
Kim-Dorner SJ; Saßmann H; Heidtmann B; Kapellen TM; Kordonouri O; Nettelrodt KME; Schweizer R; von Sengbusch S; Lange K
Heliyon; 2024 Mar; 10(6):e27614. PubMed ID: 38524562
[TBL] [Abstract][Full Text] [Related]
8. Patients' Satisfaction, Diabetic Control and Associated Factors at a Tertiary Health Facility in Rivers State, Nigeria.
John A; Ndukwu G; Dienye P
Niger Med J; 2023; 64(4):508-523. PubMed ID: 38952882
[TBL] [Abstract][Full Text] [Related]
9. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Ceriello A; Prattichizzo F; Berra CC; Caballero AE
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894-895. PubMed ID: 37996193
[No Abstract] [Full Text] [Related]
10. Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
Jacobsen SL; Köhler-Forsberg O; Rohde C
Schizophr Res; 2024 Jun; 270():231-234. PubMed ID: 38936114
[No Abstract] [Full Text] [Related]
11. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
Wilding J; Fernando K; Milne N; Evans M; Ali A; Bain S; Hicks D; James J; Newland-Jones P; Patel D; Viljoen A
Diabetes Ther; 2018 Oct; 9(5):1757-1773. PubMed ID: 30039249
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
[TBL] [Abstract][Full Text] [Related]
14. Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.
Miyagi M; Uchino H; Kumashiro N; Higa M; Shin K; Sasamoto M; Kitazato H; Tamaki M; Matsuhisa M; Hirose T
Diabetes Ther; 2018 Oct; 9(5):1959-1968. PubMed ID: 30121725
[TBL] [Abstract][Full Text] [Related]
15. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
[TBL] [Abstract][Full Text] [Related]
16. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Bailey CJ; Marx N
Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Diabetes in Patients with Heart Failure.
Bowes CD; Lien LF; Butler J
Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
Sharma A; Ambrosy AP; DeVore AD; Margulies KB; McNulty SE; Mentz RJ; Hernandez AF; Michael Felker G; Cooper LB; Lala A; Vader J; Groake JD; Borlaug BA; Velazquez EJ
ESC Heart Fail; 2018 Dec; 5(6):1035-1043. PubMed ID: 30120812
[TBL] [Abstract][Full Text] [Related]
20. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Wittmann I; Kempler P
Diabetes Ther; 2018 Oct; 9(5):2133-2141. PubMed ID: 30120754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
